Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols* (Sativex(®) ), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis

A. Novotna, J. Mares, S. Ratcliffe, I. Novakova, M. Vachova, O. Zapletalova, C. Gasperini, C. Pozzilli, L. Cefaro, G. Comi, P. Rossi, Z. Ambler, Z. Stelmasiak, A. Erdmann, X. Montalban, A. Klimek, P. Davies and the Sativex Spasticity Study Group

. 2011 ; 18 (9) : 1122-1131. [pub] 20110301

Language English Country England, Great Britain

Document type Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't

Persistent link   https://www.medvik.cz/link/bmc12024461

BACKGROUND:   Spasticity is a disabling complication of multiple sclerosis, affecting many patients with the condition. We report the first Phase 3 placebo-controlled study of an oral antispasticity agent to use an enriched study design. METHODS:   A 19-week follow-up, multicentre, double-blind, randomized, placebo-controlled, parallel-group study in subjects with multiple sclerosis spasticity not fully relieved with current antispasticity therapy. Subjects were treated with nabiximols, as add-on therapy, in a single-blind manner for 4weeks, after which those achieving an improvement in spasticity of ≥20% progressed to a 12-week randomized, placebo-controlled phase. RESULTS:   Of the 572 subjects enrolled, 272 achieved a ≥20% improvement after 4weeks of single-blind treatment, and 241 were randomized. The primary end-point was the difference between treatments in the mean spasticity Numeric Rating Scale (NRS) in the randomized, controlled phase of the study. Intention-to-treat (ITT) analysis showed a highly significant difference in favour of nabiximols (P=0.0002). Secondary end-points of responder analysis, Spasm Frequency Score, Sleep Disturbance NRS Patient, Carer and Clinician Global Impression of Change were all significant in favour of nabiximols. CONCLUSIONS:   The enriched study design provides a method of determining the efficacy and safety of nabiximols in a way that more closely reflects proposed clinical practice, by limiting exposure to those patients who are likely to benefit from it. Hence, the difference between active and placebo should be a reflection of efficacy and safety in the population intended for treatment.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc12024461
003      
CZ-PrNML
005      
20150901094651.0
007      
ta
008      
120815s2011 enk d f 000 0eng||
009      
AR
024    7_
$a 10.1111/j.1468-1331.2010.03328.x $2 doi
035    __
$a (PubMed)21362108
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Novotná, Alena, $u Krajska nemocnice Pardubice, Neurologicke odd, Paradubice, Czech Republic, novotna-alena@quick.cz $d 1964- $7 xx0079406
245    12
$a A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols* (Sativex(®) ), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis / $c A. Novotna, J. Mares, S. Ratcliffe, I. Novakova, M. Vachova, O. Zapletalova, C. Gasperini, C. Pozzilli, L. Cefaro, G. Comi, P. Rossi, Z. Ambler, Z. Stelmasiak, A. Erdmann, X. Montalban, A. Klimek, P. Davies and the Sativex Spasticity Study Group
520    9_
$a BACKGROUND:   Spasticity is a disabling complication of multiple sclerosis, affecting many patients with the condition. We report the first Phase 3 placebo-controlled study of an oral antispasticity agent to use an enriched study design. METHODS:   A 19-week follow-up, multicentre, double-blind, randomized, placebo-controlled, parallel-group study in subjects with multiple sclerosis spasticity not fully relieved with current antispasticity therapy. Subjects were treated with nabiximols, as add-on therapy, in a single-blind manner for 4weeks, after which those achieving an improvement in spasticity of ≥20% progressed to a 12-week randomized, placebo-controlled phase. RESULTS:   Of the 572 subjects enrolled, 272 achieved a ≥20% improvement after 4weeks of single-blind treatment, and 241 were randomized. The primary end-point was the difference between treatments in the mean spasticity Numeric Rating Scale (NRS) in the randomized, controlled phase of the study. Intention-to-treat (ITT) analysis showed a highly significant difference in favour of nabiximols (P=0.0002). Secondary end-points of responder analysis, Spasm Frequency Score, Sleep Disturbance NRS Patient, Carer and Clinician Global Impression of Change were all significant in favour of nabiximols. CONCLUSIONS:   The enriched study design provides a method of determining the efficacy and safety of nabiximols in a way that more closely reflects proposed clinical practice, by limiting exposure to those patients who are likely to benefit from it. Hence, the difference between active and placebo should be a reflection of efficacy and safety in the population intended for treatment.
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a dvojitá slepá metoda $7 D004311
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a roztroušená skleróza $x komplikace $x farmakoterapie $7 D009103
650    _2
$a svalová spasticita $x farmakoterapie $x etiologie $7 D009128
650    _2
$a rostlinné extrakty $x terapeutické užití $7 D010936
655    _2
$a časopisecké články $7 D016428
655    _2
$a randomizované kontrolované studie $7 D016449
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Mareš, Jan $7 xx0060341 $u Neurologicka Klinika, Olomouc, Czech Republic
700    1_
$a Ratcliffe, S. $u MAC UK Neuroscience Ltd, Manchester, UK
700    1_
$a Nováková, Iveta, $d 1971- $7 xx0079116 $u MS Centrum, Neurologicka klinika, Prague, Czech Republic
700    1_
$a Vachová, Marta $7 xx0100083 $u MS centre of Hospital Teplice, Teplice, Czech Republic
700    1_
$a Zapletalová, Olga, $d 1947- $7 utb2009546667 $u Neurologicka klinika FN Ostrava, Ostrava, Czech Republic
700    1_
$a Gasperini, C. $u Reparto Neurologico LANCISI Day Hospital, Centro Sclerosi Multipla, Rome, Italy
700    1_
$a Pozzilli, C. $u Dipartimento di Scienze Neurologiche, Universita' degli Studi, Rome, Italy
700    1_
$a Cefaro, L. $u Sant'Andrea Multiple Sclerosis Centre, University La Sapienza, Rome, Italy
700    1_
$a Comi, Giancarlo, $d 1947- $7 xx0054868 $u Centro Sclerosi Multipla Ospedale S. Raffaele, Milan, Italy
700    1_
$a Rossi, P. $u Centro Sclerosi Multipla Ospedale S. Raffaele, Milan, Italy
700    1_
$a Ambler, Zdeněk, $d 1940-2013 $7 jn19990201003 $u Neurologicka klinika FN Plzen, Plezn, Czech Republic
700    1_
$a Stelmasiak, Z. $u Katedra i Klinika Neurologii Akademii Medycznej, Lublin, Poland
700    1_
$a Erdmann, A. $u Pain Clinic F, Edith Cavell Hospital, Peterbrough, UK
700    1_
$a Montalban, X. $u Hospital Universitari de la Vall d'Hebron, Antigua Escuela de Enfermeria, Barcelona, Spain
700    1_
$a Klimek, A. $u Klinika Neurologii i Epileptologii z Oddzialem Udarowym, Lodz, Poland
700    1_
$a Davies, P. $u Department of Neurology, Northampton General Hospital, Northampton, UK
773    0_
$w MED00001629 $t European journal of neurology the official journal of the European Federation of Neurological Societies $x 1468-1331 $g Roč. 18, č. 9 (2011), s. 1122-1131
856    41
$u https://pubmed.ncbi.nlm.nih.gov/21362108 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y m $z 0
990    __
$a 20120815 $b ABA008
991    __
$a 20150901094811 $b ABA008
999    __
$a ok $b bmc $g 946609 $s 781789
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2011 $b 18 $c 9 $d 1122-1131 $e 20110301 $i 1468-1331 $m European journal of neurology $n Eur J Neurol $x MED00001629
LZP    __
$b NLK118 $a Pubmed-20120815/12/02
Back

Find record

Citation metrics

Archiving options